BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1045 related articles for article (PubMed ID: 10952840)

  • 21. A pilot study of subcutaneous recombinant hirudin (HBW 023) in the treatment of deep vein thrombosis.
    Schiele F; Vuillemenot A; Kramarz P; Kieffer Y; Soria J; Soria C; Camez A; Mirshahi MC; Bassand JP
    Thromb Haemost; 1994 May; 71(5):558-62. PubMed ID: 8091380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of a low-molecular-weight heparin (nadroparin calcium) and unfractionated heparin as adjunct to coronary thrombolysis with alteplase and aspirin in dogs.
    Jun L; Arnout J; Vanhove P; Dol F; Lormeau JC; Herbert JM; Collen D; Van de Werf F
    Coron Artery Dis; 1995 Mar; 6(3):257-63. PubMed ID: 7788040
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials.
    Mehta SR; Boden WE; Eikelboom JW; Flather M; Steg PG; Avezum A; Afzal R; Piegas LS; Faxon DP; Widimsky P; Budaj A; Chrolavicius S; Rupprecht HJ; Jolly S; Granger CB; Fox KA; Bassand JP; Yusuf S;
    Circulation; 2008 Nov; 118(20):2038-46. PubMed ID: 18955665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacodynamic and safety results of PEG-Hirudin in healthy volunteers.
    Esslinger HU; Haas S; Maurer R; Lassmann A; Dübbers K; Müller-Peltzer H
    Thromb Haemost; 1997 May; 77(5):911-9. PubMed ID: 9184402
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of prolonged dalteparin treatment on coagulation, fibrinolysis and inflammation in unstable coronary artery disease.
    Oldgren J; Fellenius C; Boman K; Jansson JH; Nilsson TK; Wallentin L; Siegbahn A
    J Intern Med; 2005 Nov; 258(5):420-7. PubMed ID: 16238677
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction.
    Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS
    Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thrombin activity throughout the acute phase of acute ST-elevation myocardial infarction and the relation to outcome.
    Ulrich-Möckel NV; Riehle M; Vollert J; Heller G; Störk T; Riess H; Müller C; Frei U; Möckel M
    Biomarkers; 2009 Aug; 14(5):311-6. PubMed ID: 19552570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparative efficacy of once daily parnaparin and unfractionated heparin in unstable angina pectoris: PRIME CARE study.
    PRIME CARE Study Investigators Group
    Indian Heart J; 2005; 57(6):648-54. PubMed ID: 16521631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relationship of cardiac troponin T and procoagulant activity in unstable angina.
    Giannitsis E; Bardorff MM; Schweikart S; Wiegand U; Kampmann M; Katus HA
    Thromb Haemost; 2000 Feb; 83(2):224-8. PubMed ID: 10739377
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of a low molecular weight heparin (Fragmin) and of unfractionated heparin on coagulation activation at the site of plug formation in vivo.
    Eichinger S; Wolz M; Nieszpaur-Los M; Schneider B; Lechner K; Eichler HG; Kyrle PA
    Thromb Haemost; 1994 Dec; 72(6):831-5. PubMed ID: 7740450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
    Anand SS
    Am J Cardiol; 1999 Sep; 84(5A):13M-19M. PubMed ID: 10505538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Antithrombin therapy in acute coronary syndromes].
    Maseri A; Andreotti F; Biasucci LM; Rebuzzi AG
    Cardiologia; 1994 Dec; 39(12 Suppl 1):7-13. PubMed ID: 7634317
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. Helvetica Investigators.
    Serruys PW; Herrman JP; Simon R; Rutsch W; Bode C; Laarman GJ; van Dijk R; van den Bos AA; Umans VA; Fox KA
    N Engl J Med; 1995 Sep; 333(12):757-63. PubMed ID: 7643882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clopidogrel-rt-PA-heparin combination in the treatment of acute myocardial infarction.
    Bassand JP; Cariou R; Grollier G; Kragten J; Wolf JE; Heyndrickx GR
    Semin Thromb Hemost; 1999; 25 Suppl 2():69-75. PubMed ID: 10440428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H; Videm V; Wahba A; Asberg A; Amundsen T; Bjella L; Dale O; Stenseth R
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparison of the antithrombotic effect of the new recombinant hirudin HBW 023 and heparin in small arteries and veins.
    Zhang B; Wieslander JB
    Microsurgery; 1996; 17(2):89-96. PubMed ID: 8914063
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Recombinant hirudin for unstable angina pectoris. A multicenter, randomized angiographic trial.
    Topol EJ; Fuster V; Harrington RA; Califf RM; Kleiman NS; Kereiakes DJ; Cohen M; Chapekis A; Gold HK; Tannenbaum MA
    Circulation; 1994 Apr; 89(4):1557-66. PubMed ID: 8149521
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of the antithrombotlic effect and safety between intravenous nadroparin and unfractionated heparin in patients undergoing percutaneous coronary intervention].
    Zhu JH; Qiu YG; Chen JZ; Zhang FR; Fu GS; Shen FR; Huang WJ; Wang JA; Zhao LL; Tao QM; Zheng LR
    Zhonghua Xin Xue Guan Bing Za Zhi; 2005 Apr; 33(4):335-9. PubMed ID: 15932664
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant nematode anticoagulant protein c2 in patients with non-ST-segment elevation acute coronary syndrome: the ANTHEM-TIMI-32 trial.
    Giugliano RP; Wiviott SD; Stone PH; Simon DI; Schweiger MJ; Bouchard A; Leesar MA; Goulder MA; Deitcher SR; McCabe CH; Braunwald E;
    J Am Coll Cardiol; 2007 Jun; 49(25):2398-407. PubMed ID: 17599602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.